Volunteer studies of deletion mutants of Vibrio cholerae O1 prepared by recombinant techniques
- PMID: 3335402
- PMCID: PMC259251
- DOI: 10.1128/iai.56.1.161-167.1988
Volunteer studies of deletion mutants of Vibrio cholerae O1 prepared by recombinant techniques
Abstract
Vibrio cholerae O1 A-B- vaccine strain JBK 70 and A-B+ CVD 101 prepared by recombinant DNA techniques from pathogenic EI Tor Inaba N16961 and classical Ogawa 395, respectively, were fed to 38 volunteers in single doses of 10(4) to 10(10). Although severe diarrhea did not occur in any vaccine, more than one-half developed mild diarrhea. These attenuated strains colonized well and elicited prominent vibriocidal and antitoxic (CVD 101) antibody responses. Recipients of a single dose of JBK 70 were significantly protected when challenged with 10(6) wild-type N16961. Diarrhea occurred in 7 of 8 controls but in only 1 of 10 vaccines (P less than 0.003, 89% vaccine efficacy), demonstrating the potency of immune mechanisms that do not involve cholera antitoxin. Further derivatives were prepared to explore the pathogenesis of the residual diarrhea, considering that either intestinal colonization by the vaccine itself or accessory toxins might be responsible. CVD 102, an auxotrophic mutant of CVD 101, did not cause diarrhea but colonized poorly and elicited feeble immune responses. Derivatives of JBK 70 and CVD 101 (CVD 104 and 105) deleted of genes encoding the EI Tor hemolysin still caused mild diarrhea. Genetically engineered strains can be colonizing, highly immunogenic, and protective single-dose oral vaccines, but they must be further attenuated before they can be considered for use as public health tools.
Similar articles
-
Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination.Infect Immun. 1999 Dec;67(12):6341-5. doi: 10.1128/IAI.67.12.6341-6345.1999. Infect Immun. 1999. PMID: 10569747 Free PMC article. Clinical Trial.
-
Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR.Lancet. 1988 Aug 27;2(8609):467-70. doi: 10.1016/s0140-6736(88)90120-1. Lancet. 1988. PMID: 2900401 Clinical Trial.
-
Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru.Infect Immun. 1997 Sep;65(9):3852-6. doi: 10.1128/iai.65.9.3852-3856.1997. Infect Immun. 1997. PMID: 9284163 Free PMC article. Clinical Trial.
-
A review of the current status of enteric vaccines.P N G Med J. 1995 Dec;38(4):325-31. P N G Med J. 1995. PMID: 9522876 Review.
-
PaxVax CVD 103-HgR single-dose live oral cholera vaccine.Expert Rev Vaccines. 2017 Mar;16(3):197-213. doi: 10.1080/14760584.2017.1291348. Expert Rev Vaccines. 2017. PMID: 28165831 Review.
Cited by
-
Indirect measurement of intestinal immune responses to an orally administered attenuated bacterial vaccine.Infect Immun. 1992 May;60(5):2023-9. doi: 10.1128/iai.60.5.2023-2029.1992. Infect Immun. 1992. PMID: 1563793 Free PMC article.
-
Analysis of expression of toxin-coregulated pili in classical and El Tor Vibrio cholerae O1 in vitro and in vivo.Infect Immun. 1992 Oct;60(10):4278-84. doi: 10.1128/iai.60.10.4278-4284.1992. Infect Immun. 1992. PMID: 1356927 Free PMC article.
-
Toxin, toxin-coregulated pili, and the toxR regulon are essential for Vibrio cholerae pathogenesis in humans.J Exp Med. 1988 Oct 1;168(4):1487-92. doi: 10.1084/jem.168.4.1487. J Exp Med. 1988. PMID: 2902187 Free PMC article.
-
Purification and characterization of novel toxin produced by Vibrio cholerae O1.Infect Immun. 1999 Oct;67(10):5215-22. doi: 10.1128/IAI.67.10.5215-5222.1999. Infect Immun. 1999. PMID: 10496898 Free PMC article.
-
CTX genetic element encodes a site-specific recombination system and an intestinal colonization factor.Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3750-4. doi: 10.1073/pnas.90.8.3750. Proc Natl Acad Sci U S A. 1993. PMID: 8475125 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases